{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:35:48Z","timestamp":1794537348826,"version":"4.9.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0A0522N"],"award-info":[{"award-number":["G0A0522N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Historically, onchocerciasis has been recognised for its dermatological and ophthalmological manifestations, such as blindness. However, growing epidemiological evidence indicates that onchocerciasis is also associated with neurological complications, particularly onchocerciasis-associated epilepsy (OAE). These complications are not currently reflected in disease burden estimates and associated disability-adjusted life years (DALYs) for onchocerciasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main text<\/jats:title>\n            <jats:p>The most recent global burden of disease estimates for onchocerciasis in 2019 reported 1.23 million DALYs without accounting for OAE. Yet, a preliminary study suggested that 128,000\u00a0years of life lost to disability (YLD, a key component of DALYs) may be attributable to epilepsy in onchocerciasis-endemic areas of East and Central Africa. This figure, which would represent over 13% of the total onchocerciasis morbidity burden and 10% of the global epilepsy morbidity burden, is likely still an underestimation. Current disability weights for epilepsy YLD estimation may not fully capture the spectrum of OAE, which often involves nodding syndrome, developmental delays, motor disabilities, cognitive impairments and stigma. In regions where access to antiseizure medication treatment is sparse, poorly controlled seizures can exacerbate disability and lead to premature mortality. Targeted integrated strategies\u2014combining onchocerciasis control measures with improved epilepsy care\u2014could help address these critical gaps.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Recognising OAE as part of the disease burden associated with onchocerciasis may encourage global health stakeholders to allocate resources for targeted interventions, thereby refining disease burden estimates, reducing disability, averting premature deaths and improving overall health outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s40249-025-01297-6","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T02:11:14Z","timestamp":1743214274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recognising the neurological burden of onchocerciasis: the need to include onchocerciasis-associated epilepsy in onchocerciasis global health metrics"],"prefix":"10.1186","volume":"14","author":[{"given":"Lu\u00eds-Jorge","family":"Amaral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1919-1340","authenticated-orcid":false,"given":"Robert","family":"Colebunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"1","key":"1297_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40249-024-01260-x","volume":"13","author":"YS Zhu","year":"2024","unstructured":"Zhu YS, Sun ZS, Zheng JX, Zhang SX, Yin JX, Zhao HQ, et al. Prevalence and attributable health burdens of vector-borne parasitic infectious diseases of poverty, 1990\u20132021: findings from the Global burden of disease study 2021. Infect Dis Poverty. 2024;13(1):96.","journal-title":"Infect Dis Poverty"},{"key":"1297_CR2","unstructured":"World Health Organisation. Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030. WHO\/UCN\/NTD\/2020.01. 2021. 2021."},{"key":"1297_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2024.04.018","author":"G Van Cutsem","year":"2024","unstructured":"Van Cutsem G, Siewe Fodjo JN, Hadermann A, Amaral LJ, Trevisan C, Pion S, et al. Onchocerciasis-associated epilepsy: charting a path forward. Seizure. 2024. https:\/\/doi.org\/10.1016\/j.seizure.2024.04.018.","journal-title":"Seizure."},{"issue":"8","key":"1297_CR4","doi-asserted-by":"publisher","first-page":"e1260","DOI":"10.1016\/S2214-109X(23)00248-6","volume":"11","author":"SR Jada","year":"2023","unstructured":"Jada SR, Amaral LJ, Lakwo T, Carter JY, Rovarini J, Bol YY, et al. Effect of onchocerciasis elimination measures on the incidence of epilepsy in Maridi, South Sudan: a 3-year longitudinal, prospective, population-based study. Lancet Glob Health. 2023;11(8):e1260\u20138.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"1297_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011178","volume":"17","author":"D Bhwana","year":"2023","unstructured":"Bhwana D, Amaral LJ, Mhina A, Hayuma PM, Francis F, Siewe Fodjo JN, et al. Impact of a bi-annual community-directed treatment with ivermectin programme on the incidence of epilepsy in an onchocerciasis-endemic area of Mahenge, Tanzania: a population-based prospective study. PLoS Negl Trop Dis. 2023;17(6): e0011178.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"1297_CR6","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","volume":"10","author":"GBD Epilepsy Collaborators","year":"2025","unstructured":"GBD Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990\u20132021: a systematic analysis for the Global burden of disease study 2021. Lancet Public Health. 2025;10(3):e203\u201327.","journal-title":"Lancet Public Health"},{"issue":"12","key":"1297_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012325","volume":"18","author":"SH Woromogo","year":"2024","unstructured":"Woromogo SH, Garoua-Adjou SI, Ngouyombo AD, Doyama-Woza RH, Diemer HSC, Longo JD. Factors associated with Onchocerca volvulus transmission after 20 years of community treatment with ivermectin in Savanah and forest areas in Central African Republic: a cross sectional study. PLoS Negl Trop Dis. 2024;18(12): e0012325.","journal-title":"PLoS Negl Trop Dis"},{"key":"1297_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.seizure.2023.07.006","volume":"110","author":"JN Siewe Fodjo","year":"2023","unstructured":"Siewe Fodjo JN, Van Cutsem G, Amaral LJ, Colebunders R. Mortality among persons with epilepsy in onchocerciasis-endemic and non-endemic areas of sub-Saharan Africa: a systematic review and meta-analysis. Seizure. 2023;110:253\u201361.","journal-title":"Seizure"},{"issue":"1","key":"1297_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40249-018-0481-9","volume":"7","author":"NVS Vinkeles Melchers","year":"2018","unstructured":"Vinkeles Melchers NVS, Mollenkopf S, Colebunders R, Edlinger M, Coffeng LE, Irani J, et al. Burden of onchocerciasis-associated epilepsy: first estimates and research priorities. Infect Dis Poverty. 2018;7(1):101.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"1297_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40249-015-0068-7","volume":"4","author":"TGN Ton","year":"2015","unstructured":"Ton TGN, Mackenzie C, Molyneux DH. The burden of mental health in lymphatic filariasis. Infect Dis Poverty. 2015;4(1):34.","journal-title":"Infect Dis Poverty"},{"key":"1297_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihae051","author":"JN Siewe Fodjo","year":"2024","unstructured":"Siewe Fodjo JN, Jada SR, Rovarini J, Bol YY, Carter JY, Hadermann A, et al. Accelerating onchocerciasis elimination in humanitarian settings: lessons from South Sudan. Int Health. 2024. https:\/\/doi.org\/10.1093\/inthealth\/ihae051.","journal-title":"Int Health."},{"key":"1297_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18230","author":"D Bhwana","year":"2024","unstructured":"Bhwana D, Amaral LJ, Kamoen O, Mhina A, Mushi V, Makunde W, et al. Community-based epilepsy care in an onchocerciasis-endemic area: a 3-year cohort study in Mahenge, Tanzania. Epilepsia. 2024. https:\/\/doi.org\/10.1111\/epi.18230.","journal-title":"Epilepsia."}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-025-01297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-025-01297-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-025-01297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T02:11:20Z","timestamp":1743214280000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-025-01297-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1186\/s40249-025-01297-6","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}